The lens in hereditary hyperferritinaemia cataract syndrome contains crystalline deposits of L-ferritin

Andrew D Mumford, Ian A Cree, Jayantha D Arnold, Myles C Hagan, Kenneth C Rixon, John J Harding

Abstract

Background/aim—Hereditary hyperferritinaemia cataract syndrome (HHCS) is an autosomal dominant disorder characterised by elevated serum L-ferritin and bilateral cataracts. The ocular manifestations of this disorder are poorly studied. This study therefore sought to determine the origin of cataracts in HHCS.

Methods—L-ferritin ELISA, immuno-histochemical and ultrastructural analysis of a lens nucleus from an HHCS individual.

Results—The HHCS lens L-ferritin content was 147 µg/g dry weight of lens compared with <16 µg/g for a non–HHCS control cataract lens. The cataract comprised discrete crystalline inclusions with positive staining with anti-L-ferritin but not anti-H-ferritin.

Conclusions—This unusual finding of crystalline opacities in the lens may be unique to HHCS and is likely to result from disturbed metabolism of L-ferritin within the lens or an abnormal interaction between L-ferritin and lens proteins.

Ferritin in human tissues exists as a 24-mer protein containing variable proportions of 21 kD H-chains and 19 kD L-chains. Ferritin is an intracellular iron storage protein protecting tissues from oxidative damage by sequestration, oxidation, and nucleation of free iron in a central cavity. Both L-ferritin and H-ferritin genes contain a highly conserved sequence in the 5'-untranslated region that encodes a cis acting regulatory sequence in the m-RNA termed the iron responsive element (IRE). The IRE interacts with an inhibitory isoform acting cytoplasmic iron binding protein, the iron regulatory peptide (IRP), so that when intracellular iron concentrations are low, translation of the ferritin mRNA is prevented. Conversely, when iron concentrations increase, IRP-IRE binding is disrupted and ferritin synthesis proceeds.

Disturbed regulation of L-ferritin synthesis occurs in families with the recently recognised hereditary hyperferritinaemia cataract syndrome (HHCS). Affected individuals show homozygous point mutations or deletions within the L-ferritin IRE and the resultant changes in the secondary structure of the IRE may prevent efficient interaction with the IRP. L-ferritin synthesis is then not subject to the normal inhibitory influence of the iron dependent IRP. The characteristic phenotype of this disorder is a fivefold to 20-fold increase in serum L-ferritin concentration and the development of sutural lens opacities. Even in the more severely affected individuals, a greatly increased rate of ferritin synthesis is not associated with abnormal iron metabolism and the only demonstrable clinical abnormality is the formation of cataracts. The mechanism of formation of cataracts in affected individuals is unknown.

In this report we describe the biochemical and histological analysis of lens tissue from an individual with a severe HHCS phenotype and demonstrate that the lens contains crystalline deposits of immunoreactive L-ferritin.

Patients and methods

CASE REPORT

The 53 year old woman was identified as part of an 11 member family spanning three generations with HHCS. Six individuals showed the HHCS phenotype with cataracts and serum ferritin concentrations ranging from 902–1452 µg/l (normal range 15–250 µg/l). Affected individuals were heterozygous for a A to G point mutation in the L-ferritin m-RNA at position +40 relative to the translation start site (Paris-1 mutation). Five affected individuals underwent ocular examination. Fine anterior and posterior sutural opacities were identified in a 10 month old individual and other family members, these appeared to increase in density with the increasing age of the individual (Fig 1).

In the adults, the cortical opacities were more prominent near the lens equator but extending axially. In the proband, the cataract is visible as a central sutural opacity extending radially. In the adults, the cortical opacities were more prominent near the lens equator but extending axially with increasing age. No other ocular abnormalities were demonstrated. The sequence of sutural opacities followed by radiating cortical opacity was reminiscent of the appearance of cataracts developing in diabetic rats.

Figure 1 Slit lamp appearance of the lens from the proband. The cataract is visible as a central sutural opacity within the lens with additional cortical opacities visible extending radially. In the adults, the cortical opacities were more prominent near the lens equator but extending axially with increasing age. No other ocular abnormalities were demonstrated. The sequence of sutural opacities followed by radiating cortical opacity was reminiscent of the appearance of cataracts developing in diabetic rats.
nent near the lens equator but extending axially with increasing age. No other ocular abnormalities were demonstrated. The subject had a serum ferritin concentration of 1449 µg/l and developed visual symptoms from her cataracts in her early twenties. She underwent extracapsular cataract extraction with intraocular lens implantation shortly after HHCS was diagnosed. The lens nucleus was immediately divided with approximately half of the material placed into formaldehyde solution for histological analysis. The remainder was transported unfixed for determination of L-ferritin concentration. A control cataract lens nucleus from an age and sex matched individual without HHCS was also obtained for biochemical analysis.

L-FERRITIN ELISA
Unfixed lens samples were stored at −20°C until freeze drying and homogenisation in coating buffer (35 mM sodium bicarbonate, 15 mM sodium carbonate pH 9.6, 17.46 mg/l phenylmethyl sulphonyl fluoride) to a concentration of 10 mg/ml. Aliquots of 300 µg were pipetted into a 96 well microplate and the volume made up to 100 µl with coating buffer. Incubation of 2 hours at 20°C and 16 hours at 4°C was followed by blotting and washing with TBS-T (10 mM TRIS-hydrochloride (Sigma), 140 mM NaCl, pH 7.4). Wells were blocked with 1% bovine serum albumin (BSA) in TBS-T for 30 minutes at 20°C followed by further washing with TBS-T. Polyclonal rabbit anti-human L-ferritin (Sigma) was diluted 1/500 in TBS-T and 100 µl added to the wells for 90 minutes at 20°C. Washing with TBS-T was followed by the addition of 100 µl of a 1/500 dilution in TBS-T of monoclonal anti-rabbit IgG (clone RG-96) alkaline phosphatase conjugate (Sigma) for 90 minutes at room temperature. Wells were again washed in TBS-T and 50 µl of Sigma 104 phosphatase substrate and colour reagent in colour development solution (100 mM TRIS, 100 mM NaCl, 5 mM magnesium chloride (Sigma) added for 20 minutes. A volume of 50 µl of 0.1 M NaOH was added followed by plate reading at 405 nm. Control and subject lens homogenates were subjected to four separate analyses and were compared to ferritin standards from 13.6 ng to 64 ng (horse spleen ferritin).

HISTOLOGICAL ANALYSIS
A small portion of lens was placed in glutaraldehyde for electron microscopy, post-fixed in osmium tetroxide, and stained with lead acetate. Ultrathin sections were prepared from 1 mm blocks and viewed under a Jeol 1010 transmission electron microscope. The remaining material was processed through to paraformaldehyde for electron microscopy, post-fixed in osmium tetroxide, and stained with lead acetate. Immunohistochemistry was performed using monoclonal antibodies to L-ferritin and H-ferritin (gift from Dr P Arosio, Milan, Italy), diluted 1:50, and sections incubated for 1 hour in TRIS buffered saline. The presence of bound antibody was detected using an streptavidin-biotin (ABC) kit (Dako Ltd) according to the manufacturer’s instructions. Diaminobenzidine was used to detect the presence of peroxidase labelled bound antibody.

Results
L-ferritin ELISA of freeze dried lens showed mean L-ferritin content of 147 µg/g dry weight of lens (range 108–201 µg/g). The control lenses had no detectable L-ferritin by this assay (<16 µg/g).

On light microscopy, the lens opacities appeared as amorphous poorly eosinophilic deposits scattered throughout the lens stroma. With monoclonal anti-L-ferritin there was dense staining of the deposits (Fig 2A). With monoclonal anti-H-ferritin staining was absent from both the lens stroma and deposits (Fig

Figure 2 (A) Light microscopic appearance of crystalline inclusions within the lens stroma showing dense staining with monoclonal anti-L-ferritin (×400). Staining was absent from the lens stroma itself. (B) The deposits were not stained with anti-H-ferritin (×400). (C) Appearance of inclusions at ×50 000 magnification showing square-shaped crystal morphology. The crystals were not associated with any cellular elements, but appeared to lie free within the stroma.
inclusions.\textsuperscript{5} The presence of such unusual deposits appears unique to the lens and is likely to be a manifestation of the unique anatomical and biochemical properties of this tissue.

Ferritin polymers synthesised in vitro by HHCS lymphoblasts are a mixture of L-chain homopolymers or L-chain rich heteropolymers and are associated with only small quantities of iron.\textsuperscript{11} It is likely therefore that these abnormal polymers are cleared rapidly. The lens appears to be unusual in that the turnover of radiolabelled L-ferritin in cultured lens epithelium is very slow.\textsuperscript{1} It is possible that the lens acquires a higher load of L-ferritin in HHCS compared with other tissues simply because of its poor catabolic activity. Furthermore, L-ferritin deposits in the lens nucleus in HHCS, the only intact material available at cataract extraction, is likely to represent ferritin synthesised decades before the development of visual symptoms because proteins in this part of the lens are not renewed.\textsuperscript{12} When protein synthesis ceases in the maturing lens fibre an acquired ferritin load would be immortalised in the lens fibre.

Slow catabolic clearance of ferritin may not be the only explanation for cataract formation. One might speculate that L-ferritin was soluble initially and did not scatter light unduly. With age the protein may have suffered post-translational modification, as happens to other proteins in the lens.\textsuperscript{13} Protein deposits are seen in a variety of diseases including amyloid diseases, prion diseases\textsuperscript{14} and in senile cataract.\textsuperscript{15} These are characterised by the presence of misfolded or unfolded protein. It is possible that slow post-translational modification of ferritin in the lens causes a conformational change to a form that aggregates. Alternatively the change in aggregation properties could be due to a change in the protein surface, analogous to the aggregation of haemoglobin S. The high molecular weight of L-ferritin aggregates may also be significant. Undesirable interactions between damaged or abnormal lens proteins are prevented by \( \alpha \) crystallin acting as a molecular chaperone.\textsuperscript{16 17} \( \alpha \) Crystallin is a large protein with a central cavity.\textsuperscript{18} If protection is normally within the cavity, then ferritin molecules would be too big to be protected from detrimental external interactions especially as ferritin has a cavity of its own.
The lens in hereditary hyperferritinaemia cataract syndrome contains crystalline deposits of L-ferritin

Andrew D Mumford, Ian A Cree, Jayantha D Arnold, Myles C Hagan, Kenneth C Rixon and John J Harding

Br J Ophthalmol 2000 84: 697-700
doi: 10.1136/bjo.84.7.697

Updated information and services can be found at:
http://bjo.bmj.com/content/84/7/697

These include:

References
This article cites 16 articles, 6 of which you can access for free at:
http://bjo.bmj.com/content/84/7/697#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Lens and zonules (807)
Eye (globe) (708)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/